Leaders in Supply & Demand Side Intelligence

Forgot your login?

Enter the e-mail address you used when you registered an account with IIR Energy.

A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.


Gilead Bolsters Cancer Portfolio with $21 Billion Immunomedics Buy, an Industrial Info Market Brief

Free News Article
Attachment Included

While the quest for a COVID-19 vaccine garners the most attention in the news, there are obviously a plethora of other conditions that require treatment. Near the top of desired therapeutics are oncology (cancer) drugs. Biotech Gilead recently signed a $21 billion deal to purchase breast cancer drug developer Immunomedics Incorporated.

Details on this Article:
Industry Segment: Market Brief
Word Count: 146 Words
Attachment: Map
Listen to Today's News News Audio Library Sync News Podcasts

Login or Register now for instant access!
Related Articles


This article is free for all Registered Members.

Register Now! All Fields are Required...

Pricing Help?

Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361

All Members Receive the Following Free Resources:

  • North American Project & Gap Spending
  • North American Plant Analysis by Industry & Market Region
  • Market Maps & Stats - Capital & Maintenance Activity
  • Current & Historic Economic Indicators
  • 30/60/90 Day Weather Forecast